The purpose of this study Phase 1 is to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic effects of intravenous DT-216 in adult patients with Friedreich Ataxia. This single ascending dose study is randomized, double-blind, placebo-controlled.
Friday, March 18, 2022
Study to Evaluate DT-216 in Adult Patients With Friedreich Ataxia
ClinicalTrials.gov Identifier: NCT05285540. First Posted : March 17, 2022
Subscribe to:
Posts (Atom)
